Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia

Jeffrey R. Bishop, James L. Reilly, Margret S H Harris, Shitalben R. Patel, Rick Kittles, Judith A. Badner, Konasale M. Prasad, Vishwajit L. Nimgaonkar, Matcheri S. Keshavan, John A. Sweeney

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Rationale: Type-3 metabotropic glutamate receptor gene (GRM3) single nucleotide polymorphisms (SNPs) have been associated with cognitive performance and prefrontal cortex brain activity in chronically treated schizophrenia patients. Whether these SNPs are associated with cognitive and symptom response to antipsychotic therapy has not been extensively evaluated. Objectives: The aim of the study was to examine pharmacogenetic relationships between GRM3 and selected variants in relevant dopamine genes with changes in spatial working memory and clinical symptoms after treatment. Methods: Sixty-one untreated first-episode schizophrenia patients were assessed before and after 6 weeks of antipsychotic pharmacotherapy, primarily consisting of risperidone. Patients' level of cognitive performance on a spatial working memory task was assessed with a translational oculomotor paradigm. Changes after treatment in cognitive and clinical measures were examined in relationship to genetic polymorphisms in the GRM3, COMT, and DRD2/ANKK1 gene regions. Results: Spatial working memory performance worsened after antipsychotic treatment. This worsening was associated with GRM3 rs1468412, with the genetic subgroup of patients known to have altered glutamate activity having greater adverse changes in working memory performance after antipsychotic treatment. Negative symptom improvement was associated with GRM3 rs6465084. There were no pharmacogenetic associations between DRD2/ANKK1 and COMT with working memory changes or symptom response to treatment. Conclusions: These findings suggest important pharmacogenetic relationships between GRM3 variants and changes in cognition and symptom response with exposure to antipsychotics. This information may be useful in identifying patients susceptible to adverse cognitive outcomes associated with antipsychotic treatment and suggest that glutamatergic mechanisms contribute to such effects.

Original languageEnglish (US)
Pages (from-to)145-154
Number of pages10
JournalPsychopharmacology
Volume232
Issue number1
DOIs
StatePublished - 2015

Fingerprint

Pharmacogenetics
Short-Term Memory
Antipsychotic Agents
Schizophrenia
Genes
Therapeutics
Single Nucleotide Polymorphism
Neurobehavioral Manifestations
Risperidone
Genetic Polymorphisms
metabotropic glutamate receptor 3
Prefrontal Cortex
Cognition
Glutamic Acid
Dopamine
Drug Therapy
Brain
Spatial Memory

Keywords

  • Antipsychotic
  • Cognition
  • COMT
  • Dopamine
  • DRD2
  • Glutamate
  • GRM3
  • Pharmacogenetics
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia. / Bishop, Jeffrey R.; Reilly, James L.; Harris, Margret S H; Patel, Shitalben R.; Kittles, Rick; Badner, Judith A.; Prasad, Konasale M.; Nimgaonkar, Vishwajit L.; Keshavan, Matcheri S.; Sweeney, John A.

In: Psychopharmacology, Vol. 232, No. 1, 2015, p. 145-154.

Research output: Contribution to journalArticle

Bishop, JR, Reilly, JL, Harris, MSH, Patel, SR, Kittles, R, Badner, JA, Prasad, KM, Nimgaonkar, VL, Keshavan, MS & Sweeney, JA 2015, 'Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia', Psychopharmacology, vol. 232, no. 1, pp. 145-154. https://doi.org/10.1007/s00213-014-3649-4
Bishop, Jeffrey R. ; Reilly, James L. ; Harris, Margret S H ; Patel, Shitalben R. ; Kittles, Rick ; Badner, Judith A. ; Prasad, Konasale M. ; Nimgaonkar, Vishwajit L. ; Keshavan, Matcheri S. ; Sweeney, John A. / Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia. In: Psychopharmacology. 2015 ; Vol. 232, No. 1. pp. 145-154.
@article{5aafe148d40a4810b14bc7e62a36307b,
title = "Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia",
abstract = "Rationale: Type-3 metabotropic glutamate receptor gene (GRM3) single nucleotide polymorphisms (SNPs) have been associated with cognitive performance and prefrontal cortex brain activity in chronically treated schizophrenia patients. Whether these SNPs are associated with cognitive and symptom response to antipsychotic therapy has not been extensively evaluated. Objectives: The aim of the study was to examine pharmacogenetic relationships between GRM3 and selected variants in relevant dopamine genes with changes in spatial working memory and clinical symptoms after treatment. Methods: Sixty-one untreated first-episode schizophrenia patients were assessed before and after 6 weeks of antipsychotic pharmacotherapy, primarily consisting of risperidone. Patients' level of cognitive performance on a spatial working memory task was assessed with a translational oculomotor paradigm. Changes after treatment in cognitive and clinical measures were examined in relationship to genetic polymorphisms in the GRM3, COMT, and DRD2/ANKK1 gene regions. Results: Spatial working memory performance worsened after antipsychotic treatment. This worsening was associated with GRM3 rs1468412, with the genetic subgroup of patients known to have altered glutamate activity having greater adverse changes in working memory performance after antipsychotic treatment. Negative symptom improvement was associated with GRM3 rs6465084. There were no pharmacogenetic associations between DRD2/ANKK1 and COMT with working memory changes or symptom response to treatment. Conclusions: These findings suggest important pharmacogenetic relationships between GRM3 variants and changes in cognition and symptom response with exposure to antipsychotics. This information may be useful in identifying patients susceptible to adverse cognitive outcomes associated with antipsychotic treatment and suggest that glutamatergic mechanisms contribute to such effects.",
keywords = "Antipsychotic, Cognition, COMT, Dopamine, DRD2, Glutamate, GRM3, Pharmacogenetics, Schizophrenia",
author = "Bishop, {Jeffrey R.} and Reilly, {James L.} and Harris, {Margret S H} and Patel, {Shitalben R.} and Rick Kittles and Badner, {Judith A.} and Prasad, {Konasale M.} and Nimgaonkar, {Vishwajit L.} and Keshavan, {Matcheri S.} and Sweeney, {John A.}",
year = "2015",
doi = "10.1007/s00213-014-3649-4",
language = "English (US)",
volume = "232",
pages = "145--154",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia

AU - Bishop, Jeffrey R.

AU - Reilly, James L.

AU - Harris, Margret S H

AU - Patel, Shitalben R.

AU - Kittles, Rick

AU - Badner, Judith A.

AU - Prasad, Konasale M.

AU - Nimgaonkar, Vishwajit L.

AU - Keshavan, Matcheri S.

AU - Sweeney, John A.

PY - 2015

Y1 - 2015

N2 - Rationale: Type-3 metabotropic glutamate receptor gene (GRM3) single nucleotide polymorphisms (SNPs) have been associated with cognitive performance and prefrontal cortex brain activity in chronically treated schizophrenia patients. Whether these SNPs are associated with cognitive and symptom response to antipsychotic therapy has not been extensively evaluated. Objectives: The aim of the study was to examine pharmacogenetic relationships between GRM3 and selected variants in relevant dopamine genes with changes in spatial working memory and clinical symptoms after treatment. Methods: Sixty-one untreated first-episode schizophrenia patients were assessed before and after 6 weeks of antipsychotic pharmacotherapy, primarily consisting of risperidone. Patients' level of cognitive performance on a spatial working memory task was assessed with a translational oculomotor paradigm. Changes after treatment in cognitive and clinical measures were examined in relationship to genetic polymorphisms in the GRM3, COMT, and DRD2/ANKK1 gene regions. Results: Spatial working memory performance worsened after antipsychotic treatment. This worsening was associated with GRM3 rs1468412, with the genetic subgroup of patients known to have altered glutamate activity having greater adverse changes in working memory performance after antipsychotic treatment. Negative symptom improvement was associated with GRM3 rs6465084. There were no pharmacogenetic associations between DRD2/ANKK1 and COMT with working memory changes or symptom response to treatment. Conclusions: These findings suggest important pharmacogenetic relationships between GRM3 variants and changes in cognition and symptom response with exposure to antipsychotics. This information may be useful in identifying patients susceptible to adverse cognitive outcomes associated with antipsychotic treatment and suggest that glutamatergic mechanisms contribute to such effects.

AB - Rationale: Type-3 metabotropic glutamate receptor gene (GRM3) single nucleotide polymorphisms (SNPs) have been associated with cognitive performance and prefrontal cortex brain activity in chronically treated schizophrenia patients. Whether these SNPs are associated with cognitive and symptom response to antipsychotic therapy has not been extensively evaluated. Objectives: The aim of the study was to examine pharmacogenetic relationships between GRM3 and selected variants in relevant dopamine genes with changes in spatial working memory and clinical symptoms after treatment. Methods: Sixty-one untreated first-episode schizophrenia patients were assessed before and after 6 weeks of antipsychotic pharmacotherapy, primarily consisting of risperidone. Patients' level of cognitive performance on a spatial working memory task was assessed with a translational oculomotor paradigm. Changes after treatment in cognitive and clinical measures were examined in relationship to genetic polymorphisms in the GRM3, COMT, and DRD2/ANKK1 gene regions. Results: Spatial working memory performance worsened after antipsychotic treatment. This worsening was associated with GRM3 rs1468412, with the genetic subgroup of patients known to have altered glutamate activity having greater adverse changes in working memory performance after antipsychotic treatment. Negative symptom improvement was associated with GRM3 rs6465084. There were no pharmacogenetic associations between DRD2/ANKK1 and COMT with working memory changes or symptom response to treatment. Conclusions: These findings suggest important pharmacogenetic relationships between GRM3 variants and changes in cognition and symptom response with exposure to antipsychotics. This information may be useful in identifying patients susceptible to adverse cognitive outcomes associated with antipsychotic treatment and suggest that glutamatergic mechanisms contribute to such effects.

KW - Antipsychotic

KW - Cognition

KW - COMT

KW - Dopamine

KW - DRD2

KW - Glutamate

KW - GRM3

KW - Pharmacogenetics

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84923324971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923324971&partnerID=8YFLogxK

U2 - 10.1007/s00213-014-3649-4

DO - 10.1007/s00213-014-3649-4

M3 - Article

C2 - 25096017

AN - SCOPUS:84923324971

VL - 232

SP - 145

EP - 154

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 1

ER -